The Boehringer Ingelheim Venture Fund was established in 2010 as an evergreen CVC, growing from an initial €100M allocation to €350M (roughly $400M). The fund has made 70+ investments including fund-in-fund positions, with 40+ currently in the portfolio.
Focus areas include immuno-oncology, regenerative medicine, infectious diseases, and digital health. Check sizes run €500K to €15M with a 5-7 ye...
Stockholm, Sweden
Berlin, Germany
Boston, United States
Helsinki, Finland
Basel, Switzerland
New York, United States